Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Sep-Oct;24(5):442-7.
doi: 10.1016/j.urolonc.2005.08.011.

Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer

R Houston Thompson  1 , James P Allison, Eugene D Kwon
Affiliations
Review

Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer

R Houston Thompson et al. Urol Oncol. 2006 Sep-Oct.

Abstract

Costimulatory pathway ligands and receptors can deliver either positive or negative signals to help determine the ultimate fate of activated T lymphocytes. Cytotoxic T lymphocyte antigen-4 (CTLA-4) represents one of the most extensively studied receptors in the costimulatory pathway and has recently been shown to function as a potent inhibitor of T cell-mediated immunity. T-cell expression of CTLA-4 indirectly facilitates tumor progression by restraining host antitumoral immunity. In contrast, administration of a monoclonal antibody to block CTLA-4 function can alleviate restraints on T-cell activity to promote immune-mediated tumor regression. We review the preclinical and clinical experience with CTLA-4 blockade as a promising immunotherapeutic approach to treat patients with advanced prostate cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
T-cell activation requires 2 independent signals. First, antigen is presented to the T-cell receptor (TCR) via an antigen/major histocompatibility complex (MHC). A second antigen independent signal, termed costimulation, is required to govern the fate of the T cell. (A) When the T-cell receptor CD28 interacts with its counter-receptor B7-1/2, a positive T-cell response is generated. (B) In the presence of CTLA-4, T-cell responses are abrogated, and tolerance of presented antigen is allowed. (Color version of figure is available online.)
Fig. 2
Fig. 2
Although required for T-cell activation, the antigen-T-cell receptor interaction does not govern the fate of the T cell. Positive costimulatory molecules, such as CD28, 4-1BB, inducible costimulator, and OX40 can stimulate a T-cell response specific for the antigen presented. On the other hand, negative costimulatory molecules, such as CTLA-4, B7-H1/PD-1. B7-H4, and BLTA can inhibit T-cell activation, and may induce anergy (tolerance) to the presented antigen. (Color version of figure is available online.)
Fig. 3
Fig. 3
Monoclonal antibody blockade of CTLA-4 allows CD28 to interact with its B7 family counter-receptor, thus stimulating a tumor specific T-cell response. (Color version of figure is available online.)
See this image and copyright information in PMC

References

    1. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445–80. - PubMed
    1. Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565–94. - PubMed
    1. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305–34. - PubMed
    1. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4:336–47. - PubMed
    1. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest. 2002;109:295–9. - PMC - PubMed